news
-
19 December 2019Axonics® Granted Six U.S. Patents and Allowed Three Additional Patents Related to its Implantable Sacral Neuromodulation Technology
Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing novel implantable Sacral Neuromodulation (“SNM”) devicesfor the treatment of bladder and bowel dysfunction, today announced that the United States Patent and Trademark Office has issued or allowed Axonics nine U.S. utility patents in 2019, along with numerous foreign counterparts relating to its implantable sacral neuromodulation technology.
The U.S. patents range in subject matter and include coverage of the Axonics lead design, patient remote control, external trial system, wireless charging, current control stimulation, electromyography and internal system electronics. The U.S. patents are: 10,478,619; 10,406,369; 10,384,067; 10,376,704; 10,447,083; 10,449,277 and 15/719,461; 15/416,888; 15/980,642.
“The volume, subject matter diversity, and breadth of important geographies demonstrate the investment in innovation that Axonics continues to make in the miniaturized and rechargeable sacral neuromodulation technology space,” said Raymond W. Cohen, Chief Executive Officer.
The Axonics patent portfolio represents technology internally developed by Axonics and technology developed under license from the Alfred Mann Foundation.
The Axonics r-SNM® System has obtained U.S. Food & Drug Administration (FDA) approval, European CE Mark approval, Health Canada approval, and Australian Therapeutic Goods Administration approval for the treatment of overactive bladder, urinary retention and fecal incontinence.
Currently, Axonics is in the initial phase of its launch in the United States following FDA approvals in September and November 2019. The Company has been marketing in select countries in Europe and Canada since the second half of 2018.
Related
Axonics® Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares
Sanford Health Now Implanting Axonics® Sacral Neuromodulation Systems
Axonics® Announces Pricing of Public Offering of Common Stock
Axonics® Announces U.S. Food & Drug Administration Approval for its Sacral Neuromodulation System
Axonics® Announces Second Quarter 2019 Financial Results and Operational Update
Axonics® Announces 1-Year Top-Line Clinical Results from its ARTISAN-SNM Pivotal Study
Axonics® Announces Publication of ARTISAN Clinical Study Results in the Journal of Urology
Axonics® Announces First Quarter 2019 Financial Results and Operational Update
Axonics® Announces Fourth Quarter and Full Year 2018 Financial Results and Operational Update
Axonics® Announces Positive Top-Line Clinical Data from its ARTISAN-SNM Pivotal Study
Axonics® Announces Publication of NICE Briefing
Axonics® Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares
Axonics® Receives Health Canada Approval for its Sacral Neuromodulation External Trial System
Axonics® Announces Closing of Initial Public Offering of Common Stock
Axonics Modulation Technologies, Inc. Announces Pricing of Initial Public Offering of Common Stock
Axonics® Receives Technology Innovation Award from Medtech Insight
Axonics® Receives CE Mark for its Sacral Neuromodulation External Trial System
Axonics® Completes Enrollment of U.S. FDA Pivotal Study for its Sacral Neuromodulation System
Axonics Announces $40 Million Financing
Axonics® Sacral Neuromodulation System Receives Marketing Approval in Australia
Axonics® Granted Seven New U.S. Patents Related to its Implantable Sacral Neuromodulation Technology
Axonics® Appoints Dr. Karen L. Noblett as Chief Medical Officer
Axonics Announces $20.5 Million Second Closing of its Series C Financing
Axonics Announces $14.5 Million First Close of Series C Financing
Axonics Granted Four U.S. Patents Related to its Implantable Sacral Neuromodulation Technology
Axonics Sacral Neuromodulation System Receives Marketing Approval from Health Canada
Axonics Granted New U.S. Patent Related to its Implantable Neuromodulation Technology
Axonics Sacral Neuromodulation System™ Receives MRI Conditional Labeling
Axonics Announces First Patients Treated in Sacral Neuromodulation Study
Axonics Granted Six U.S. Patents Related to its Implantable Neuromodulation Technology
Axonics Modulation Technologies Announces $38.5 Million Series B Financing